• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Aprea Therapeutics Inc.

    2/13/25 12:15:12 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APRE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Aprea Therapeutics, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    03836J201

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    03836J201


    1Names of Reporting Persons

    Stonepine Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    286,395.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    286,395.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    286,395.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  Percentage calculated based on (a) 149,221 shares of Common Stock beneficially owned by the reporting person, plus 137,174 shares of Common Stock underlying warrants beneficially owned by the reporting person, and (b) 5,434,903 shares of Common Stock outstanding on November 7, 2024, as reported in the Form 10-Q filed by the Issuer for the quarter ended September 30, 2024.


    SCHEDULE 13G

    CUSIP No.
    03836J201


    1Names of Reporting Persons

    Stonepine Capital, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    286,395.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    286,395.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    286,395.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Percentage calculated based on (a) 149,221 shares of Common Stock beneficially owned by the reporting person, plus 137,174 shares of Common Stock underlying warrants beneficially owned by the reporting person, and (b) 5,434,903 shares of Common Stock outstanding on November 7, 2024, as reported in the Form 10-Q filed by the Issuer for the quarter ended September 30, 2024.


    SCHEDULE 13G

    CUSIP No.
    03836J201


    1Names of Reporting Persons

    Stonepine GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    286,395.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    286,395.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    286,395.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Percentage calculated based on (a) 149,221 shares of Common Stock beneficially owned by the reporting person, plus 137,174 shares of Common Stock underlying warrants beneficially owned by the reporting person, and (b) 5,434,903 shares of Common Stock outstanding on November 7, 2024, as reported in the Form 10-Q filed by the Issuer for the quarter ended September 30, 2024.


    SCHEDULE 13G

    CUSIP No.
    03836J201


    1Names of Reporting Persons

    Jon M. Plexico
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    286,395.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    286,395.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    286,395.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  Percentage calculated based on (a) 149,221 shares of Common Stock beneficially owned by the reporting person, plus 137,174 shares of Common Stock underlying warrants beneficially owned by the reporting person, and (b) 5,434,903 shares of Common Stock outstanding on November 7, 2024, as reported in the Form 10-Q filed by the Issuer for the quarter ended September 30, 2024.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Aprea Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    3805 OLD EASTON ROAD, DOYLESTOWN, PENNSYLVANIA 18902
    Item 2. 
    (a)Name of person filing:

    Stonepine Capital Management, LLC, a Delaware limited liability company ("Stonepine") Stonepine Capital, L.P., a Delaware limited partnership (the "Partnership") Stonepine GP, LLC, a Delaware limited liability company (the "General Partner") Jon M. Plexico Stonepine and the General Partner are the investment adviser and general partner, respectively, of the Partnership. Mr. Plexico is the control person of Stonepine and the General Partner. The reporting persons are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Common Stock covered by this Schedule 13G.
    (b)Address or principal business office or, if none, residence:

    919 NW Bond Street, Suite 204 Bend, OR 97703
    (c)Citizenship:

    See Item 4 of the cover sheet for each reporting person.
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    03836J201
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Stonepine: 286,395 Partnership: 286,395 General Partner: 286,395 Jon M. Plexico: 286,395
    (b)Percent of class:

    Stonepine: 5.1% Partnership: 5.1% General Partner: 5.1% Jon M. Plexico: 5.1%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Stonepine: 0 Partnership: 0 General Partner: 0 Jon M. Plexico: 0

     (ii) Shared power to vote or to direct the vote:

    Stonepine: 286,395 Partnership: 286,395 General Partner: 286,395 Jon M. Plexico: 286,395

     (iii) Sole power to dispose or to direct the disposition of:

    Stonepine: 0 Partnership: 0 General Partner: 0 Jon M. Plexico: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Stonepine: 286,395 Partnership: 286,395 General Partner: 286,395 Jon M. Plexico: 286,395

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Partnership holds Common Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Stonepine Capital Management, LLC
     
    Signature:/s/ Jon M. Plexico
    Name/Title:Managing Member
    Date:02/13/2025
     
    Stonepine Capital, L.P.
     
    Signature:/s/ Jon M. Plexico
    Name/Title:Managing Member of the General Partner, Stonepine GP, LLC
    Date:02/13/2025
     
    Stonepine GP, LLC
     
    Signature:/s/ Jon M. Plexico
    Name/Title:Managing Member
    Date:02/13/2025
     
    Jon M. Plexico
     
    Signature:/s/ Jon M. Plexico
    Name/Title:Reporting person
    Date:02/13/2025
    Get the next $APRE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APRE

    DatePrice TargetRatingAnalyst
    8/20/2021Neutral → Underweight
    JP Morgan
    8/16/2021Buy → Hold
    Berenberg
    8/16/2021$6.00 → $4.00Neutral
    HC Wainwright & Co.
    8/13/2021$6.00 → $5.00Sector Perform
    RBC Capital
    8/13/2021$5.00 → $3.00Equal-Weight → Underweight
    Morgan Stanley
    More analyst ratings

    $APRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President/CEO Gilad Oren bought $10,110 worth of shares (5,500 units at $1.84), increasing direct ownership by 2% to 345,620 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      4/4/25 7:30:11 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SrVP/CFO/Prin Fin & Acct Ofcr Hamill John P. was granted 3,365 shares, increasing direct ownership by 17% to 22,733 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      3/31/25 4:31:29 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President/CEO Gilad Oren was granted 6,725 shares, increasing direct ownership by 2% to 340,120 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      3/31/25 4:30:32 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APRE
    Financials

    Live finance-specific insights

    See more
    • Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations

      BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three and six months ended June 30, 2022 and provided a business update. "This is an exciting time for Aprea as we advance our ATR program into clinical development this year, continue to progress our WEE1 program toward IND submission and leverage our unique discovery platform capabilities to build for future success," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. "We believe o

      8/11/22 4:15:00 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results

      BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc. ("Atrin") and reported financial results for the three months ended March 31, 2022. Business Operations Update:  On May 16, 2022 Aprea completed the acquisition of Atrin, a privately held biotechnology company focused on the discovery and development of novel therapeutics targeting proteins in the DNA damage response, or DDR, pathway in oncology through synthetic lethality. The Company believes its cash and cash

      5/16/22 9:21:33 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs

      BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its clinical trials of eprenetapopt in combination with azacitidine in its myeloid malignancy programs. The partial clinical hold does not apply to the Company's ongoing clinical trials in lymphoid malignancies and solid tumors, or the APR-548 clinical trial. There are approximately 20 patients currently receiving eprenetapopt in combination with azacitidine i

      8/5/21 5:00:00 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aprea Therapeutics downgraded by JP Morgan

      JP Morgan downgraded Aprea Therapeutics from Neutral to Underweight

      8/20/21 5:10:20 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics downgraded by Berenberg

      Berenberg downgraded Aprea Therapeutics from Buy to Hold

      8/16/21 7:29:48 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Aprea Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of Aprea Therapeutics with a rating of Neutral and set a new price target of $4.00 from $6.00 previously

      8/16/21 6:35:21 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APRE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

      Two programs with clinical data readouts in 2H/2025 Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing with preliminary clinical data expected in 2H/2025; Trial now open for enrollment to patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) Preliminary data for ongoing ADI-270 Phase 1 clinical trial in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC) expected in 2H/2025 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended M

      5/6/25 4:01:00 PM ET
      $ACET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio Appoints Michael Grissinger to the Board of Directors

      --Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions-- Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its Board of Directors. Mr. Grissinger brings more than four decades of experience in business development, strategy, and M&A leadership roles at global pharmaceutical companies. "We are honored to welcome Michael to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "His extensive

      4/17/25 7:00:00 AM ET
      $ACET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

      DOYLESTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today announced that a patient with HPV+ head and neck squamous cell carcinoma (HNSCC) has been dosed in the ongoing ACESOT-1051 clinical trial evaluating APR-1051. This is the first patient to be dosed in Cohort 5 (70 mg once daily) of the study. Open label data from the study are expected in the second half of 2025. WEE1 inhibition has emerged as a promising strategy for targeting tumor cells with high r

      3/31/25 8:30:00 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President/CEO Gilad Oren bought $10,110 worth of shares (5,500 units at $1.84), increasing direct ownership by 2% to 345,620 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      4/4/25 7:30:11 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President/CEO Gilad Oren bought $1,958 worth of shares (500 units at $3.92), increasing direct ownership by 0.15% to 333,395 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      10/24/24 8:30:13 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Duey Marc bought $131,700 worth of shares (30,000 units at $4.39), increasing direct ownership by 14% to 240,113 units (SEC Form 4)

      4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

      10/17/24 8:30:55 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Aprea Therapeutics Inc.

      SC 13G - Aprea Therapeutics, Inc. (0001781983) (Subject)

      10/10/24 4:07:13 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aprea Therapeutics Inc.

      SC 13G - Aprea Therapeutics, Inc. (0001781983) (Subject)

      2/14/24 8:00:11 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aprea Therapeutics Inc. (Amendment)

      SC 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)

      2/7/24 6:55:18 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APRE
    Leadership Updates

    Live Leadership Updates

    See more
    • Adicet Bio Appoints Michael Grissinger to the Board of Directors

      --Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions-- Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its Board of Directors. Mr. Grissinger brings more than four decades of experience in business development, strategy, and M&A leadership roles at global pharmaceutical companies. "We are honored to welcome Michael to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "His extensive

      4/17/25 7:00:00 AM ET
      $ACET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

      DOYLESTOWN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has engaged Philippe Pultar, MD as its senior medical advisor to support Aprea with developing and advancing APR-1051, Aprea's potential best in class WEE1 inhibitor. Dr. Pultar is a seasoned pharmaceutical executive with extensive experience in oncology, including the development of a WEE1 inhibitor (azenosertib) from early to late-stage clinical development. Dr. Pultar has vast experience in clinical development within both large and early-stag

      10/9/24 8:30:00 AM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer

      Brings proven leadership and successful track record to Halda as the company enters the next stage of growth as clinical-stage company Halda Therapeutics, a biotechnology company developing a novel class of cancer therapies called RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) therapeutics, today announced that it has appointed Christian Schade as President and Chief Executive Officer and a member of the Board of Directors. Chris brings more than 20 years of public and private pharmaceutical and biotechnology industry experience, including building, financing and leading biotechnology companies through the clinical stages of pipeline development and formation of value-creating de

      10/1/24 8:30:00 AM ET
      $APRE
      $IART
      $OMGA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)

    $APRE
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Aprea Therapeutics Inc.

      DEFA14A - Aprea Therapeutics, Inc. (0001781983) (Filer)

      4/22/25 4:15:12 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Aprea Therapeutics Inc.

      DEF 14A - Aprea Therapeutics, Inc. (0001781983) (Filer)

      4/22/25 4:05:14 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Aprea Therapeutics Inc.

      SCHEDULE 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)

      4/8/25 3:14:41 PM ET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care